Physician profile
John D Burk
NPI 1518991033
$1,583.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $282 · 2022: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $361.82 | 2019-2022 | |
| Janssen Biotech, INC. | $178.38 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $110.77 | 2019 | |
| Genzyme Corporation | $106.82 | 2019 | |
| Prugen, INC. Pharmaceuticals | $94.99 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $65.34 | 2019-2022 | |
| Ucb, INC. | $61.88 | 2019 | |
| Lilly USA, LLC | $51.36 | 2019-2020 | |
| Dermira, INC. | $40.33 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $31.57 | 2019 | |
| Galderma Laboratories, L.P. | $28.34 | 2019-2020 | |
| Pfizer INC. | $26.62 | 2019 | |
| Misonix INC | $21.43 | 2020 | |
| Melinta Therapeutics, LLC | $17.46 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $13.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.